GlassScriptPhysician profile
Wei Niu
NPI 1306333778
$3,089.12
in general payments reported to CMS, 2019-2025
21 companies · $64.67 in 2025
The $64.67 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $537 · 2023: $1,200 · 2024: $1,287 · 2025: $64.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.48 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $692.68 | 2022-2025 | |
| Genzyme Corporation | $433.35 | 2022-2024 | |
| Dermavant Sciences, INC. | $362.43 | 2022-2024 | Vtama |
| Pfizer INC. | $196.36 | 2022-2024 | |
| Lilly USA, LLC | $187.68 | 2023 | Taltz, Olumiant |
| Incyte Corporation | $181.67 | 2022-2024 | Opzelura |
| Janssen Biotech, INC. | $177.62 | 2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $138.98 | 2023-2024 | Absorica Ld, Winlevi, Ilumya |
| Leo Pharma INC. | $121.25 | 2023-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $109.09 | 2022-2024 | Sotyktu |
| Amgen INC. | $92.89 | 2022-2024 | Otezla |
| Kyowa Kirin, INC. | $74.47 | 2022 | |
| Arcutis Biotherapeutics, INC. | $60.22 | 2023-2024 | Zoryve |
| Galderma Laboratories, L.P. | $57.22 | 2023-2024 | Aklief, Oracea, Twyneo |
| Organon LLC | $44.59 | 2025 | Vtama |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $36.67 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.99 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $24.01 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.91 | 2024 | Dupixent |
| Fidia Pharma USA INC. | $22.72 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Niu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.